Ginkgo bioworks expands its r&d facilities, opens bioworks7 to conduct mammalian screening at scale, widening capabilities for biopharma partners

Newest foundry increases capacity in biopharmaceuticals, biomanufacturing and general mammalian programming for therapeutic applications boston , jan. 6, 2023 /prnewswire/ -- ginkgo bioworks (nyse: dna), which is building the leading platform for cell programming and biosecurity, today announced the opening of bioworks7, the latest expansion of its biological engineering foundry. with this new space, ginkgo increases its capacity and capabilities to serve its partners in the spaces of cell and gene therapy, biomanufacturing and general mammalian programming for therapeutic applications and new biopharmaceutical modalities.
DNA Ratings Summary
DNA Quant Ranking